Showing results (1091-1100 of 1,150) with videos related to
Sort By:
Pageof 115
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.The Canadian Journal of Cardiology|October 9, 2009
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendationsJacques Genest, Ruth McPherson, Jiri Frohlich, et al.Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.The Canadian Journal of Cardiology|January 29, 2013
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultTodd J Anderson, Jean Grégoire, Robert A Hegele, et al.Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.Scientific Reports|January 23, 2021
Development and large volume production of extremely high current density YBa2Cu3O7 superconducting wires for fusionA Molodyk, S Samoilenkov, A Markelov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.The Journal of Clinical Investigation|August 18, 2015
RAP1-mediated MEK/ERK pathway defects in Kabuki syndromeNina Bögershausen, I-Chun Tsai, Esther Pohl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.Pageof 115